August 8, 2017 - Cynvenio launches its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.
July 27, 2017 – Cynvenio announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.
Visit Cynvenio at booth #S11 on Saturday, July 29th to learn more about the latest in ClearID Liquid Biopsy testing.
April 3, 2017 – Cynvenio announces the immediate availability of two new antibody-based capture kits consisting of EGFR (epidermal growth factor receptor) and PSMA (prostate specific membrane antigen).
March 31, 2017 - Cynvenio Biosystems today announced the further expansion of its payor network with the signing of a new agreement with Blue Cross Blue Shield of Illinois (BCBS IL) allowing its members access to Cynvenio's broad menu of liquid biopsy testing services for cancer.
March 9, 2017 – Cynvenio will showcase its ClearID Total Insight Monitoring service at the 34th Annual Miami Breast Cancer Conference, the Young Survival Coalition (YSC) Summit, and the 27th Annual Interdisciplinary Breast Center Conference.
March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced the availability of ClearID® Total Insight™ Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
February 23, 2017 – Cynvenio and Color announces a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Cynvenio’s ClearID® Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer.
February 10, 2017 – Cynvenio Biosystems will feature its LiquidBiopsy rare cell isolation platform at Molecular Med Tri-Con 2017, February 19-24, 2017 in San Francisco.
January 26, 2017 - Cynvenio Biosystems, Inc. and Milenia Labs announced a distribution agreement for Cynvenio’s ClearID® Breast Cancer. The agreement will make ClearID Breast Cancer exclusively available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico.
January 9, 2017 - Cynvenio has released its updated ClearID® Breast Cancer blood test. The new ClearID test identifies circulating tumor cell burden and detects emergent genetic alterations associated with resistance to therapy, and has been optimized to monitor patients with advanced breast cancer during initiation of therapy and at regular intervals following treatment.